Phase I – First Administration to Humans

783 trials 323 recruiting

Filter these 783 trials by condition, country, sponsor and more.

Open in Search →

Safety Assessment of 10-Day Daily Bucco-Oral Administration of Transfer Factor in Healthy Adult Human Subjects Ended

2024-511448-17-02 healthy subjects 2024-10-16
Safety of TEG001 in patients with r/r AML/high-risk MDS or r/r MM Ended

2024-517381-42-00 Acute Myeloid Leukemia (AML) 2024-10-14
A trial to learn if AZD9829 is safe and works alone and in combination with other treatments for participants with certain blood cancers. Ended

2023-506997-11-00 CD123-Positive Hematological Malignancies: Module 1 foc 2024-10-09
A clinical trial to determine if AIC263029 is safe when dosed only once or several times, and to investigate how it moves within the human b… Ended

2023-510074-13-00 BKV-associated nephropathy 2024-10-02
A research study on the effects of NNC0537-1482 in healthy individuals when injected under the skin. Ended

2024-514431-18-00 Heart Failure 2024-10-01
A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Safety, Tolerability and Pharmacokinetic Study of Escalating Single and Multiple Do… Ended

2023-504426-19-00 Pulmonary fibrosis 2024-10-01
A Phase 1b, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Safety, Engraftment, and Initial Signs of Clinical Activity of MB… Ended

2023-507376-50-00 Ulcerative Colitis 2024-09-27
A Phase I Study to Evaluate Safety and Immunogenicity of DNA Vaccine N-pVAX1 against Crimean Congo Hemorrhagic Fever (CCHF-NP-1) Ended

2023-508556-18-00 Crimean Congo Hemorrhagic Fever 2024-09-25
A study to evaluate the safety and tolerability of JNJ-70035108 and to evaluate how long JNJ-70035108 stays in and acts on the body (pharmac… Ended

2024-514067-25-00 Inflammatory Conditions 2024-09-23
A phase 1 study to evaluate the dose, safety and tolerability of a radionuclide therapy (Radspherin®) in patients with platinum sensitive re… Ended

2024-511851-16-00 Platinum Sensitive Recurrent Epithelial Ovarian, Fallop 2024-09-20
A first-in-human study to learn how safe the study treatment BAY2862789 is, to find the best dose, how it affects the body, what maximum amo… Ended

2024-510998-26-00 Advanced solid tumors 2024-09-18
An open label, phase 1 study to evaluate the safety, feasibility and immunogenicity of an allogeneic, cell-based vaccine (VIDIDENCEL) in hig… Ended

2024-516781-10-00 High grade serous ovarian cancer 2024-09-16
A research study looking at how different doses of study medicine (Inno8) works in the body of healthy men. Ended

2023-506520-90-00 Prophylaxis and on-demand treatment respectively in pat 2024-09-16
A safety study of PF-08046044/SGN-35C in adults with advanced cancers Ended

2023-505813-26-00 Lymphoma, Large B-Cell, Diffuse 2024-09-12
A Study to Learn How Different Amounts and Forms of the Study Intervention Called PF-07899895 are Tolerated and Act in the Body of Healthy A… Ended

2023-507354-32-00 Ulcerative Colitis 2024-09-09
A First-in-Human, randomised, double blind, placebo-controlled, single ascending dose trial to evaluate safety, tolerability, and pharmacoki… Ended

2023-507939-38-00 Urinary tract infections (UTIs)/complicated UTI (cUTI) 2024-08-28
First-in-man clinical trial to assess safety and tolerability of CEB-01 PLGA membrane in patients with recurrent or locally advanced retrope… Ended

2024-516971-34-00 Recurrent or locally advanced retroperitoneal soft tiss 2024-08-20
A Study to Learn How Different Amounts of the Study Medicine Called PF-07940369 are Tolerated and Act in the Body in Healthy Adults. Ended

2024-513467-47-00 clonal hematopoiesis 2024-08-08
A randomized, single-center, double-blind, placebo-controlled, first-in-human trial with single and multiple ascending doses to determine sa… Ended

2024-512510-17-00 Treatment of pain 2024-08-05
A clinical study of MK-2828 in healthy people (MK-2828-001) Ended

2024-513377-51-00 Atherosclerosis 2024-08-01
A study to learn if UCB3101 is safe and how it moves through the body of healthy participants Ended

2023-504586-24-00 Healthy Participants 2024-07-31
Single Ascending Dose study of ENX-104 Ended

2024-514265-19-00 Major Depressive Disorder 2024-07-17
A study to learn how safe KER-0193 is, the activity of KER-0193 in the body over a period of time, and the effect of KER-0193 to the body in… Ended

2024-511468-94-00 Fragile X syndrome 2024-07-10
First-in-human Phase 1 Study to Assess the Safety, Tolerability, and Immunogenicity of the Adjuvanted Universal Influenza Vaccine “fH1/DSP-0… Ended

2023-504378-39-00 Influenza 2024-06-26